Circulating VEGF levels were shown to be elevated in HCC and correlated with tumor angiogenesis and progression, and an association between high tumor microvessel density and increased local and circulating VEGF with rapid disease progression and poor prognosis [100], supporting the efficacy of targeting the VEGF pathway in HCC therapy. The gene discussed is VEGFA; the disease is neoplasm.